Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
84.85 CHF | -0.18% | -1.49% | -0.02% |
Apr. 17 | Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years | MT |
Apr. 17 | Novartis: positive efficacy data in MS | CF |
Sales 2024 * | 48.13B 43.74B | Sales 2025 * | 49.85B 45.31B | Capitalization | 204B 185B |
---|---|---|---|---|---|
Net income 2024 * | 10.65B 9.68B | Net income 2025 * | 11.58B 10.53B | EV / Sales 2024 * | 4.49 x |
Net Debt 2024 * | 12.16B 11.05B | Net Debt 2025 * | 10.8B 9.81B | EV / Sales 2025 * | 4.3 x |
P/E ratio 2024 * |
18.2
x | P/E ratio 2025 * |
16.2
x | Employees | 76,057 |
Yield 2024 * |
3.92% | Yield 2025 * |
4.05% | Free-Float | 81.95% |
Latest transcript on Novartis AG
1 day | -0.18% | ||
1 week | -1.49% | ||
Current month | -2.88% | ||
1 month | -0.92% | ||
3 months | -9.40% | ||
6 months | -2.90% | ||
Current year | -0.02% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
10.40% | 121 M€ | -.--% | - | |
5.57% | 18 M€ | +2.91% | - | |
4.12% | 88 M€ | +10.37% | - | |
3.79% | 2 M€ | -25.75% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-17 | 84.85 | -0.18% | 2,429,911 |
24-04-16 | 85 | -1.73% | 3,068,722 |
24-04-15 | 86.5 | +0.46% | 2,331,975 |
24-04-12 | 86.1 | +0.55% | 2,419,969 |
24-04-11 | 85.63 | -0.58% | 2,226,966 |
Delayed Quote Swiss Exchange, April 17, 2024 at 11:31 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.02% | 204B | |
+28.79% | 676B | |
+24.81% | 554B | |
-7.64% | 349B | |
+15.00% | 318B | |
+5.99% | 291B | |
+2.47% | 210B | |
-9.98% | 194B | |
-11.71% | 144B | |
-8.32% | 142B |
- Stock Market
- Equities
- NOVN Stock